BACKGROUND: Parameningeal rhabdomyosarcoma (PM-RMS) is a rare, highly malignant pediatric tumor arising from locations adjacent to the meninges, from where it can spread intracranially. PROCEDURE: We reviewed 109 children with non-metastatic PM-RMS enrolled in the Italian RMS79, RMS88 and RMS96 protocols over a 24-year period. All patients received intensive chemotherapy and standard or hyperfractionated and accelerated radiotherapy. Some had delayed surgery. RESULTS: Five-year overall survival rose from 40% in the RMS79 to 72% in the RMS88 and RMS96 protocols (P = 0.01), where more intensive chemotherapy and hyperfractionated accelerated radiotherapy (HART) was used. Delayed surgery after initial treatment was statistically associated with a better prognosis. Unfavorable tumor characteristics for RMS arising in other sites, for example, histology, invasiveness or node involvement, did not predict outcome for PM-RMS. CONCLUSION: Outcome in PM-RMS patients enrolled in three consecutive Italian protocols has progressively improved, as a result of intensive chemotherapy, delayed surgery and, possibly, HART, though improved imaging and radiotherapeutic tools may have had a role as well. (c) 2007 Wiley-Liss, Inc.
BACKGROUND:Parameningeal rhabdomyosarcoma (PM-RMS) is a rare, highly malignant pediatric tumor arising from locations adjacent to the meninges, from where it can spread intracranially. PROCEDURE: We reviewed 109 children with non-metastatic PM-RMS enrolled in the Italian RMS79, RMS88 and RMS96 protocols over a 24-year period. All patients received intensive chemotherapy and standard or hyperfractionated and accelerated radiotherapy. Some had delayed surgery. RESULTS: Five-year overall survival rose from 40% in the RMS79 to 72% in the RMS88 and RMS96 protocols (P = 0.01), where more intensive chemotherapy and hyperfractionated accelerated radiotherapy (HART) was used. Delayed surgery after initial treatment was statistically associated with a better prognosis. Unfavorable tumor characteristics for RMS arising in other sites, for example, histology, invasiveness or node involvement, did not predict outcome for PM-RMS. CONCLUSION: Outcome in PM-RMS patients enrolled in three consecutive Italian protocols has progressively improved, as a result of intensive chemotherapy, delayed surgery and, possibly, HART, though improved imaging and radiotherapeutic tools may have had a role as well. (c) 2007 Wiley-Liss, Inc.
Authors: J H M Merks; G L De Salvo; C Bergeron; G Bisogno; A De Paoli; A Ferrari; A Rey; O Oberlin; M C G Stevens; A Kelsey; J Michalski; D S Hawkins; J R Anderson Journal: Ann Oncol Date: 2014-01 Impact factor: 32.976
Authors: Stephanie K Childs; Kevin R Kozak; Alison M Friedmann; Beow Y Yeap; Judith Adams; Shannon M MacDonald; Norbert J Liebsch; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-04 Impact factor: 7.038
Authors: Veronique Minard-Colin; David Walterhouse; Gianni Bisogno; Helene Martelli; James Anderson; David A Rodeberg; Andrea Ferrari; Meriel Jenney; Suzanne Wolden; Gianluca De Salvo; Carola Arndt; Johannes H M Merks; Soledad Gallego; Dominique Schwob; Christine Haie-Meder; Christophe Bergeron; Michael C G Stevens; Odile Oberlin; Douglas Hawkins Journal: Pediatr Blood Cancer Date: 2018-05-21 Impact factor: 3.167
Authors: Marta Pierobon; Andrea Ferrari; Giovanni Scarzello; Angela Tamburini; Lucia Quaglietta; Antonio Ruggiero; Giuseppe Maria Milano; Angelica Zin; Gianni Bisogno Journal: Neurooncol Pract Date: 2018-03-27